Trial Profile
A Centre-Randomized, Open-Label, Cross-Over Study to Compare the Pharmaco-Economic Consequences of an Ultiva (Remifentanil Hydrochloride) Based Regimen With Conventional Sedative Based Regimens in ICU Subjects Requiring Short-Term Mechanical Ventilation With Analgesia and Sedation.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Aug 2023
Price :
$35
*
At a glance
- Drugs Remifentanil (Primary) ; Hypnosedatives
- Indications Pain; Sedation
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 06 Apr 2009 New trial record